Newsroom | 22740 results

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the appointment of John P. “Jack” Kenny to its Board of Directors....

HOUSTON--(BUSINESS WIRE)--PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC, a leader in Lab-on-a-Chip non-invasive Point-of-Care diagnostics—today announced that it has received a private, third-party tendered offer involving the secondary purchase of shares from existing shareholders, reflecting an implied company valuation of approximately $1.75 billion. The tendered offer represents a continuation of PathoCare Holdings’ capital markets evolution fol...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.” Soon-Shiong is the company’s Founder, Executive Chairman and Global Chief Scientific and Medical Officer, and is a global thought leader in advancing the goal of a cancer-free society. On its website announcing the honor, OncoDaily highlighted...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that, on December 9, 2025, the Compensation Committee of Precision’s Board of Directors approved the grant of an inducement award of 8,224 restricted stock units (“RSUs”) to a new employee under the Precision BioSciences, Inc. 2021 Employment In...

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Assembly Biosciences, Inc. (Nasdaq: ASMB), today announced Gilead has exercised its combined option to exclusively license Assembly Bio’s herpes simplex virus (HSV) helicase-primase inhibitor programs, including long-acting investigational candidates ABI-1179 and ABI-5366 for recurrent genital herpes. These represent the first programs Gilead will advance under the ongoing Assembly Bio R...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with the U.S. government designed to reduce drug costs for Americans, reinforcing the company’s long-standing commitment to U.S.-based innovation, affordability, and global health leadership. “This agreement reflects a foundational commitment to both affordability and future innovation, a commitment that we have long seen as essential to shaping the future of healthcare,” said Daniel O’Day, C...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (Sede: Chuo-ku, Tokyo; Presidente e CEO: Toshiaki Nagasato) oggi ha annunciato la firma di un accordo di collaborazione con MBC BioLabs, un'organizzazione privata che supporta lo sviluppo di aziende startup biotecnologiche nella San Francisco Bay Area californiana. MBC BioLabs fornisce strutture di ricerca completamente attrezzate e una comunità di supporto che aiuta gli imprenditori del settore biotecnologico ad accelerare le operazioni dal...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (hoofdkantoor: Chuo-ku, Tokio; president en CEO: Toshiaki Nagasato) heeft vandaag bekendgemaakt dat het een samenwerkingsovereenkomst heeft gesloten met MBC BioLabs, een particuliere organisatie die de ontwikkeling van biotechnologische start-ups in de San Francisco Bay Area in Californië ondersteunt. MBC BioLabs biedt volledig uitgeruste onderzoeksfaciliteiten en een ondersteunende gemeenschap die biotechondernemers helpt om sneller van conc...

TOKIO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (sede central: Chuo-ku, Tokio; presidente y gerente general: Toshiaki Nagasato) ha anunciado hoy que ha suscrito un acuerdo de colaboración con MBC BioLabs, una organización privada que sustenta el desarrollo de las empresas emergentes de biotecnología en el área de la bahía de San Francisco, en California. MBC BioLabs ofrece instalaciones de investigación totalmente equipadas y una comunidad de apoyo que asiste a los emprendedores biotecnoló...

TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma Co., Ltd. (siège : Chuo-ku, Tokyo ; président-directeur général : Toshiaki Nagasato) a annoncé aujourd’hui avoir conclu un accord de partenariat avec MBC BioLabs, une organisation privée qui soutient le développement de startups biotechnologiques dans la région de la baie de San Francisco, en Californie. MBC BioLabs fournit des installations de recherche entièrement équipées et une communauté solidaire qui aide les entrepreneurs biotechnologiques à pas...